AVANOS MEDICAL, INC.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAvanos Medical is a medical technology company focused on enteral nutrition and non-opioid pain management products, currently under agreement to be acquired by American Industrial Partners.
What they do
Avanos Medical develops, manufactures, and markets medical devices in two segments: Specialty Nutrition Systems (SNS) and Pain Management and Recovery (PM&R). SNS products include MIC-KEY enteral feeding tubes, Corpak feeding solutions, and NeoMed neonatal products. PM&R includes ON-Q surgical pain pumps, Game Ready cold therapy, and radiofrequency ablation (RFA) products like COOLIEF and Trident.
Revenue drivers
- MIC-KEY enteral feeding tubes — A leading brand in the SNS segment, each accounted for more than 10% of consolidated net sales in 2023-2025.
- Corpak patient feeding solutions — Another SNS product line that also exceeded 10% of consolidated net sales in the same period.
- NeoMed neonatal and pediatric feeding solutions — Part of the SNS segment, contributed more than 10% of consolidated net sales annually from 2023 to 2025.
- Pain Management and Recovery (PM&R) — Includes ON-Q pumps (over 10% of net sales in 2023) and RFA products (COOLIEF over 10% in 2023); combined PM&R sales were $56.3 million in Q1 2026.
Recent performance
In Q1 2026, total net sales rose 8.8% year-over-year to $182.2 million, with SNS growing double-digit and PM&R roughly flat. Net income was $5.1 million, down from $6.6 million; adjusted EPS was $0.22 vs $0.26. Operating cash flow was negative $12.3 million, versus positive $25.7 million a year ago. Cash and debt were $65.6 million and $98.2 million, respectively, as of March 31, 2026.
Strategy
Avanos is executing a restructuring plan to align its footprint and organizational structure with its remaining business after divesting its respiratory health business; it expects incremental expenses up to $10 million and annualized savings of $15-20 million. The company is also integrating the September 2025 acquisition of Nexus Medical, which added anti-reflux needleless connector technology (TKO). Management emphasizes double-digit organic growth in SNS and steady progress on strategic imperatives.
Risks
- Competition — The industry is highly competitive, with larger, more established players and small startups; failure to compete effectively could hurt results.
- Tariffs and trade restrictions — The company has manufacturing in Mexico and cites the impact of tariffs and retaliatory trade measures as a forward-looking risk.
- Restructuring execution — The expanded restructuring plan may not achieve expected savings or could incur higher costs than anticipated.
- Merger completion risk — The pending acquisition by AIP is subject to conditions; if it fails, the stock price could decline.
Outlook
Management did not provide formal guidance, but the Q1 release highlights solid performance and momentum. The pending merger with AIP at $25.00 per share (enterprise value of $1.272 billion) is expected to close, subject to shareholder and regulatory approvals. The company continues to focus on SNS growth and cost savings from restructuring.